Life Science News

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce that it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec ("WuXi"), Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin.

Years of groundbreaking research by Sirona's team of scientists at TFChem has shown in preclinical studies that TFC-1326 has the potential to reverse the effects of aging on skin, including the potential to eliminate fine wrinkles. The scientific data is strong, and we are now preparing for a clinical trial. There are no existing compounds that our scientists are aware of, that have the potential to reverse the effects of the aging process on skin to truly restore its structure and youthful appearance. The anti-aging and anti-wrinkle markets are estimated to be $271 Billion USD globally by 2024.

We are in advanced discussions with a leading clinical trial provider designing the planned clinical trial. Other necessary steps, including formulation and safety work, is being organized. As soon as this is completed and the clinical study starts, we will provide further information on this.

"There are many anti-aging and anti-wrinkle products available on the market currently. But to truly reverse the damage to the skin integrity that occurs naturally with aging is an area of unmet need. Our goal is to demonstrate clinically the potential of TFC-1326 to restore the integrity of the skin and return a more youthful appearance. The treatment of fine wrinkles is also a goal . BOTOX® is the most effective on dynamic wrinkles while static wrinkles typically are managed by fillers. TFC-1326 has the potential to replace or supplement dermal filler injections to treat these static wrinkles," said Dr Howard Verrico, CEO of Sirona Biochem. "TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space. Like our recent success, licensing TFC-1067 and the corresponding compound family globally , we see this as another opportunity to showcase the tremendous potential of our platform technology. And, of course, we are pursuing another lucrative licensing agreement for TFC-1326."

About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver ground-breaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made, and every disease can be treated."
For more information, please visit: www.wuxiapptec.com

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading cosmetics and pharma companies around the world in return for licensing fees, milestone payments and ongoing royalty payments. Sirona's R&D unit, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

For more information regarding this press release, please contact:

Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SBM:CA
Sirona Biochem Inc.

Sirona Biochem Inc.


Keep reading...Show less
Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility

Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University's Institute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19).

Sirona's French subsidiary, TFChem, has created a novel and patentable library of 20 compounds that are designed to target the COVID-19 virus by targeting the host cell and not the virus itself. When a virus enters a cell, it induces a "cytopathic effect" which refers to structural changes in the host cell, that allow the virus to replicate. In SARS-CoV-2, the virus causes plaque-like effects in the human cells of the lung. Mechanisms such as cell fusion, apoptosis (death) and destruction of epithelium integrity are all observed in the plaque regions (Nature Communications, 2020, https://www.nature.com/articles/s41467-020-17796-z ). Sirona's antiviral compounds are intended to prevent the cytopathic effect from occurring.

The results will be completed in approximately 6 weeks.

"Since the compounds are designed to target the host cell and not the virus itself, we have a unique approach that is based on our proprietary technology . We have seen the number of variants that the SARS-CoV-2 virus has. It will continue to mutate, creating new strains, so there is a strong need for compounds like these that are not targeted to a specific virus," said Dr. Howard Verrico , CEO of Sirona Biochem. "It is now time to push this program as quickly as possible, adding to a robust and valuable pipeline that will attract the right kind of partners. For this project, we have already been in preliminary discussion with a company that has expertise in antiviral clinical trials. The results from these preliminary studies will be key to moving forward with potential partners in 2022."

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/20/c6910.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China

Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces that it has received notice that the development of Sirona's SGLT2 inhibitor, TFC-039, will be discontinued by Wanbang Biopharmaceuticals (" Wanbang ") as a treatment for type 2 diabetes in China .

TFC-039 was licensed to Wanbang, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical Group, in 2014. Sirona received a total of USD 1.5 million in up front and milestone payments.

"To this point, Wanbang has remained dedicated to the development of the drug, completing the IND and advancing through and completing its Phase I clinical trials. During 2021, they indicated that they were extensively analyzing the clinical results and that delays were the result of COVID closures and restrictions. This year, Empagliflozin (developed by Boehringer Ingelheim and Eli Lilly ) failed to uphold patent protection in China , which created a generic environment for SGLT2 inhibitors. It was reported to us TFC-039 performed well in the clinical trials, however, given the generic situation, it did not make good business sense for Wanbang to continue a lengthy and costly development", said Dr. Howard Verrico , CEO of Sirona Biochem.

"While this is disappointing, we still see a path forward for TFC-039. We are working on several opportunities (both existing and new) for animal care globally. Our science team is also working on a new therapeutic indication, with potential strong advantages for TFC-039 compared to other compounds of the same class. This new indication has both unmet need and tremendous commercial value. The work done to date by Sirona and Wanbang will provide added value towards these opportunities, and we will also explore future involvement with Wanbang. Further dialogue will be occurring between Wanbang, and Sirona and any material news will be released accordingly."

About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals

Wanbang Biopharmaceuticals develops, manufactures and sells drugs with indications for chronic disease treatment, antibiotics, and other endocrine diseases in China . Founded in 1981, they are presently headquartered in Xuzhou, China , and are a subsidiary of Shanghai Fosun Pharmaceutical Group. Fosun is a leader in the pharmaceutical industry and regarded as one of the top five domestic pharmaceutical companies in China . For more information on Fosun and Wanbang, please visit www.fosunpharma.com/en .

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/13/c8213.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
sbm tsx

Sirona Biochem Announces 2021 Annual Meeting Results: Shareholders Approve All Resolutions With Majority Vote

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF)  (" Sirona ") is pleased to announce the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on November 10, 2021 . The total number of shares represented by shareholders present in person and by proxy at the meeting was 33,335,079, representing 14.45% of Sirona's issued and outstanding Common Shares.

Sirona Biochem Corp. Logo (CNW Group/Sirona Biochem Corp.)

All matters put forward to shareholders for consideration and approval, as set out in the Company's Management Information Circular dated 12 th of October, 2021, were approved by the requisite majority of votes cast at the Meeting. These were:

1. To elect Sirona's board of directors; 2. to fix the number of directors of the Company at five; 3. to appoint DeVisser Gray LLP, Chartered Professional Accountants, as the Company's auditor for the ensuing year and authorize the directors to set the auditor's remuneration; and 4. to confirm and approve the Company's existing stock option plan.

"We thank our shareholders for their participation and continued support," said Dr. Howard Verrico , CEO of Sirona. "We look forward to further building and commercializing our pipeline."

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/10/c4848.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
sirona biochem

/R E P E A T -- Sirona Biochem: Investing News Network Interview with CEO, Dr. Howard Verrico/

Featuring an update on anticipated deal for TFC-1067

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") is pleased to inform its shareholders that a video interview with CEO, Dr. Howard Verrico has been published by Investing News Network https:investingnews.com in Vancouver BC Canada .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem: Investing News Network Interview with CEO, Dr. Howard Verrico

Sirona Biochem: Investing News Network Interview with CEO, Dr. Howard Verrico

Featuring an update on anticipated deal for TFC-1067

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") is pleased to inform its shareholders that a video interview with CEO, Dr. Howard Verrico has been published by Investing News Network https:investingnews.com in Vancouver BC Canada .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Official Launch of E-Commerce Sales Channel

The Gummy Project Announces Official Launch of E-Commerce Sales Channel

  • The Gummy Project'S Watermelon Sharks and Peachy Bees are now available for pre-sale purchase at www.shopgummies.com
  • Shipping and fulfilment of online orders will commence on July 11, 2022

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce the official launch of its new e-commerce site at www.shopgummies.com.

"The launch of our e-commerce site is a major milestone, making our product available across Canada for the first time," said Anthony Gindin, Chief Marketing Officer at GUMY. "This really marks our official launch into the Canadian market with e-commerce being a major component in our overall sales channel strategy. The site provides a vehicle for continued growth as well as a platform to share our story and fulfil our mandate to support endangered keystone species."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2022. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.

Resolutions proposed and approved at the AGM were:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

  • The Gummy Project'S Watermelon Sharks and Peachy Bees to be sold at Vancouver based Stong's Markets
  • Stong's are Vancouver owned full-service grocery stores that have operated in Vancouver since 1931

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce that as of June 29, 2022 it has partnered with Stong's to launch its Watermelon Sharks and Peachy Bees into the Canadian retail market.

"This partnership represents another great step in our ongoing sales strategy and we're extremely proud to partner with Stong's, an iconic grocery store in Vancouver," said Charlie Lamb, President and CEO of GUMY. "Following our recent partnership announcements with Flair Airlines and Bard on the Beach, the upcoming launch of our ecommerce site on June 30 2022, and our distribution partnership with Dean's Dairy and Specialty Foods, consumers will soon be able to purchase our products at locations across Canada."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Health Canada Approves OPDIVO® as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma at High Risk of Recurrence after Undergoing Radical Resection of UC

First adjuvant Immunotherapy for patients at high risk of disease recurrence

Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of Compliance with Conditions (NOCc) for OPDIVO ® , as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. i OPDIVO ® is the first immuno-oncology treatment to bring benefit in the adjuvant setting of UC and represents a potential new standard of care for patients at high risk of disease recurrence. ii Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognize and attack cancer cells. iii

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Pivotal ZUMA-5 Study Demonstrates Overall Response Rate of 91% and a Complete Response rate of 77% in Patients Who Received Yescarta After Three or More Lines of Therapy –

Kite's Third Approved Cell Therapy Indication in Europe

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

NDA Resubmission Addresses Issues Related to Vial Compatibility –

If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×